Literature DB >> 6235727

The murine antitumor immune response and its therapeutic manipulation.

R J North.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6235727     DOI: 10.1016/s0065-2776(08)60575-1

Source DB:  PubMed          Journal:  Adv Immunol        ISSN: 0065-2776            Impact factor:   3.543


× No keyword cloud information.
  39 in total

1.  Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma.

Authors:  F P Holladay; T Heitz-Turner; W L Bayer; G W Wood
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

Review 2.  Translating tumor antigens into cancer vaccines.

Authors:  Luigi Buonaguro; Annacarmen Petrizzo; Maria Lina Tornesello; Franco M Buonaguro
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

3.  A2A Adenosine Receptor Gene Deletion or Synthetic A2A Antagonist Liberate Tumor-Reactive CD8+ T Cells from Tumor-Induced Immunosuppression.

Authors:  Jorgen Kjaergaard; Stephen Hatfield; Graham Jones; Akio Ohta; Michail Sitkovsky
Journal:  J Immunol       Date:  2018-05-25       Impact factor: 5.422

4.  Antigraft responses to the H-28c antigen by B6 and B6D2F1 mice.

Authors:  L L Johnson
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

5.  Chemo-immunotherapy of murine tumors using interleukin-2 (IL-2) and cyclophosphamide. IL-2 can facilitate or inhibit tumor growth depending on the sequence of treatment and the tumor type.

Authors:  E Kedar; R Ben-Aziz; E Epstein; B Leshem
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  Comparative methodologies of regulatory T cell depletion in a murine melanoma model.

Authors:  Norimasa Matsushita; Shari A Pilon-Thomas; Lisa M Martin; Adam I Riker
Journal:  J Immunol Methods       Date:  2008-02-13       Impact factor: 2.303

7.  Chemotherapy-induced modulation of natural killer and lymphokine-activated killer cell activity in euthymic and athymic mice.

Authors:  Z Gazit; E Kedar
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

8.  Synergistic antitumor activity of cyclophosphamide and ABPP in the treatment of established and advanced tumors in murine tumor models.

Authors:  A M Eggermont; P H Sugarbaker; R L Marquet; J Jeekel
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

9.  The influence of cyclophosphamide on antitumor immunity in mice bearing late-stage tumors.

Authors:  F Culo; I Klapan; T Kolak
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

10.  Immunological tolerance and tumor rejection in embryo-aggregated chimeric mice - lessons for tumor immunity.

Authors:  Alexander Y Wagner; Eric Holle; Lori Holle; Xianzhong Yu; Günter Schwamberger
Journal:  BMC Cancer       Date:  2008-12-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.